167 related articles for article (PubMed ID: 7827902)
1. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer.
Beets G; Penninckx F; Schiepers C; Filez L; Mortelmans L; Kerremans R; Aerts R; De Roo M
Br J Surg; 1994 Nov; 81(11):1666-70. PubMed ID: 7827902
[TBL] [Abstract][Full Text] [Related]
2. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
Imdahl A; Reinhardt MJ; Nitzsche EU; Mix M; Dingeldey A; Einert A; Baier P; Farthmann EH
Langenbecks Arch Surg; 2000 Mar; 385(2):129-34. PubMed ID: 10796051
[TBL] [Abstract][Full Text] [Related]
4. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
Jörg L; Langsteger W
Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
[TBL] [Abstract][Full Text] [Related]
5. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
7. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
9. Role of positron emission tomography in staging esophageal cancer.
Luketich JD; Schauer PR; Meltzer CC; Landreneau RJ; Urso GK; Townsend DW; Ferson PF; Keenan RJ; Belani CP
Ann Thorac Surg; 1997 Sep; 64(3):765-9. PubMed ID: 9307471
[TBL] [Abstract][Full Text] [Related]
10. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
11. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
12. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
14. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
15. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
[TBL] [Abstract][Full Text] [Related]
16. Staging recurrent metastatic colorectal carcinoma with PET.
Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
[TBL] [Abstract][Full Text] [Related]
17. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
18. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
19. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
